• Publications
  • Influence

Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage publications (all current information on this profile has been aggregated automatically from publisher and metadata sources).
  • Charles M. Rudin, Maria Catherine Pietanza, +20 authors David Robert Spigel
  • Medicine
  • The Lancet. Oncology
  • 2017
  • BACKGROUND Rovalpituzumab tesirine is a first-in-class antibody-drug conjugate directed against delta-like protein 3 (DLL3), a novel target identified in tumour-initiating cells and expressed in moreContinue Reading
  • Charles M. Rudin, Maria Catherine Pietanza, +13 authors Stanford Peng
  • Medicine
  • 2016 (First Publication: 20 May 2016)
  • LBA8505Background: SCLC remains among the most deadly of malignancies. Rovalpituzumab tesirine is a first-in-class ADC comprised of a humanized monoclonal antibody against DLL3, a dipeptide linker,Continue Reading
  • Todd Michael Bauer, David Robert Spigel, +11 authors Charles M. Rudin
  • Medicine
  • Journal of thoracic oncology : official…
  • 2016 (First Publication: 1 November 2016)
  • All Treated Patients (TC2/3 or IC2/3) Cohort 1 (1L) 139 24% (17-32) 7.3 (5.6-9.1) 20.1 (20.1-NE) Cohort 2 (2L) 268 19% (15-24) 2.8 (2.6-4.1) 15.5 (12.3-NE) Cohort 3 (3L+) 252 19% (15-25) 3.0Continue Reading